RBMY2XP

Q-omics provides the consensus-scored RBMY2XP profile across patient tissues and cancer cell-line models. RBMY2XP expression is associated with patient survival in 1 of 34 cancer types, with the highest sampling consensus in KIRC. Additionally, RBMY2XP RNA expression shows 1 significant protein co-abundance associations, with the highest sampling consensus in CCRCC. Together, these results highlight KIRC, and CCRCC as cancer lineages where RBMY2XP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.

Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.

Survival associations

This table summarizes RBMY2XP survival associations across molecular data types. RBMY2XP RNA expression shows survival associations in the most cancer types (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.

RBMY2XP data type	Survival analysis	Lineage consensus	Lineage of highest sampling consensus
RNA	Kaplan–Meier	1	KIRC (36)	view →

This table ranks reproducible RBMY2XP RNA expression–survival associations across cancer types. High RBMY2XP expression shows unfavorable associations in KIRC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .021). Together, the overview and detailed table identify KIRC as the clearest survival context for RBMY2XP RNA expression.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	OS	Tertile	All	0.138	0.655	.021	36	view →

Pink = unfavorable, green = favorable. all 1 lineages →

RBMY2XP-KIRC (OS)

Explore this curve interactively →